Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Columbia University
Gemtuzumab ozogamicin with cytarabine effective in elderly AML patients
September 24th, 2004
A regimen of gemtuzumab ozogamicin (GO) and cytarabine can be effective for elderly acute myeloid leukemia (AML) patients. GO, "an anti-CD33 monoclonal antibody conjugated to calicheamicin, is effective as single agent in the treatment of poor risk" AML patients, oncologists in New York explained. P.P. Piccaluga and colleagues at Columbia University "treated with GO in combination with cytarabine as continuous perfusion nine elderly AML patients, either untreated (five cases), or with relapsed/refractory disease (four cases)." "Five patients achieved a complete remission (CR), four were resistant," the researchers said. "One...
Source: Food & Drug Law Weekly (2004-09-24)
|
